News | May 06, 2007

Angioblast Systems’ Trial Approved — Texas Heart to Investigate Use of Adult Stem Cells to Repair Heart Attack Damage

May 7, 2007 — Australia's adult stem cell company, Mesoblast Limited, has announced that the FDA has cleared the Investigational New Drug Submission (IND) of its U.S.-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf,’ adult stem cells for patients with heart attacks.

"FDA clearance is a significant step towards commercializing our stem cell products in the U.S., the world's largest market for cardiovascular diseases," said founder and chief scientific adviser, Professor SilviuItescu. "Importantly FDA clearance was obtained within 30 days of the submission of the IND," he said.

The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company's proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure.

The clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack. The trial will use the latest generation catheters provided through Angioblast's ongoing relationship with the Johnson & Johnson companies, Cordis Corp. and Biosense Webster.

The commercial strategy for both Mesoblast and Angioblast is to generate high margin stem cell products that are obtained from a single donor, expanded, frozen, and subsequently used in thousands of unrelated, or allogeneic, recipients at the time and place of need.

Over one million new patients with heart attacks are treated annually in the U.S. alone, representing a multibillion-dollar market opportunity. Current therapies do not result in rebuilding of heart muscle, and do not prevent progression of congestive heart failure, poor quality of life, and long-term deterioration.

For more information visit www.mesoblast.com

Related Content

Renovacor Closes $11 Million Series A Financing for New Cardiovascular Gene Therapy
News | Stem Cell Therapies | August 22, 2019
August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion o
Placental Stem Cells Can Regenerate the Heart After Heart Attack
News | Stem Cell Therapies | May 20, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta...
ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init